Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
argenx SE - American Depositary Shares
(NQ:
ARGX
)
569.12
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 8, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about argenx SE - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Argenx Shares Drop After Q1 Miss, But Retail Traders Call Sub-$550 ‘An Absolute Steal’
May 08, 2025
Despite the Q1 miss, management reiterated confidence in its long-term “Vision 2030” strategy, highlighting strong Vyvgart uptake in gMG and CIDP and the recent U.S. approval of a self-injection...
Via
Stocktwits
Topics
Earnings
Exposures
Financial
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings
May 08, 2025
Via
Benzinga
Exposures
Fossil Fuels
Argenx Beats Sales Expectations — But Not By Enough — And Shares Tumble
May 08, 2025
The company's drug treats two autoimmune conditions and recently launched with a prefilled synringe for at-home treatment.
Via
Investor's Business Daily
Earnings Scheduled For May 8, 2025
May 08, 2025
Via
Benzinga
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
May 08, 2025
From
argenx SE
Via
GlobeNewswire
A Look Into argenx Inc's Price Over Earnings
May 07, 2025
Via
Benzinga
P/E Ratio Insights for argenx
April 29, 2025
Via
Benzinga
What's Driving the Market Sentiment Around argenx?
April 21, 2025
Via
Benzinga
argenx to Present at BofA Securities 2025 Health Care Conference
May 06, 2025
From
argenx SE
Via
GlobeNewswire
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
May 01, 2025
From
argenx SE
Via
GlobeNewswire
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
April 28, 2025
From
argenx SE
Via
GlobeNewswire
P/E Ratio Insights for argenx
March 20, 2025
Via
Benzinga
What Analysts Are Saying About argenx Stock
March 04, 2025
Via
Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
March 04, 2025
Via
Benzinga
Does ARGENX SE - ADR (NASDAQ:ARGX) meet the Minervini criteria?
April 26, 2025
A fundamental and technical analysis of (NASDAQ:ARGX): Is ARGENX SE - ADR (NASDAQ:ARGX) suited for high growth investing?
Via
Chartmill
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
April 21, 2025
Via
Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
April 18, 2025
Via
Benzinga
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
April 11, 2025
FDA approves Argenx's Vyvgart Hytrulo prefilled syringe for self-injection in gMG and CIDP, offering flexible dosing and expanding treatment options.
Via
Benzinga
Exposures
Product Safety
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
April 11, 2025
From
argenx SE
Via
GlobeNewswire
Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug
April 11, 2025
The prefilled syringe will cost 4% more than the under-the-skin shot.
Via
Investor's Business Daily
Exposures
Product Safety
What 11 Analyst Ratings Have To Say About argenx
April 11, 2025
Via
Benzinga
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
April 11, 2025
Via
Benzinga
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
April 10, 2025
From
argenx SE
Via
GlobeNewswire
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
April 09, 2025
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.
Via
Benzinga
Topics
Government
Supply Chain
World Trade
Exposures
Political
Supply Chain
Tariff
Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients
April 08, 2025
Argenx reports long-term Vyvgart data showing lasting efficacy in gMG and CIDP, with strong safety and symptom control across multiple studies.
Via
Benzinga
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
April 08, 2025
From
argenx SE
Via
GlobeNewswire
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
March 31, 2025
Via
Benzinga
Looking Into argenx's Recent Short Interest
March 26, 2025
Via
Benzinga
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
March 07, 2025
From
argenx SE
Via
GlobeNewswire
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
March 04, 2025
Analysts remains bullish on the company's chances in depression and epilepsy. But investors aren't convinced.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.